Unsupervised PrEP in routine practice: a new challenge?

Hélène Laroche (1) , Caroline Lions (1) , Olivia Zaegel-Faucher (1) , Catherine Tamalet (2) , Isabelle Poizot-Martin (1, 3)

1 Service d'Immuno-hématologie clinique [Hôpital Sainte Marguerite - APHM]
2 TIMONE - Hôpital de la Timone [CHU - APHM]
3 SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale

Pre-exposure prophylaxis (PrEP) for the prevention of HIV infection with 300 mg daily tenofovir co-formulated with 200 mg emtricitabine is recommended as one prevention option for people who are at substantial risk of acquiring an HIV infection. We report the case of a 28-year-old man who has sex with men and who was referred to our unit for a primary HIV infection with positive p18, p24 and gp160 bands on Western blot analysis but with a low HIV plasma viral load. Although HIV misdiagnosis should always be considered in cases of atypical seroconversion pattern with a low viral burden, unsupervised PrEP should be systematically investigated.

Mots clés: Prevention; human immunodeficiency virus; sexual behaviour; diagnosis; treatment

Domaines: Santé publique et épidémiologie

Hélène Laroche, Caroline Lions, Olivia Zaegel-Faucher, Catherine Tamalet, Isabelle Poizot-Martin. Unsupervised PrEP in routine practice: a new challenge?. International Journal of STD and AIDS, 2019, 30 (7), pp.715-717. ⟨10.1177/0956462419828872⟩. ⟨hal-02613510⟩